Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gimatecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 19/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | GLA | P06280 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | HNRNPA1 | P09651 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gimatecan SCHEMBL24685122 | 1.00 | TOP1 (0.79) | TOP1ALDH1A1GLAMEN1KMT2A | |
| Gimatecan SCHEMBL15341182 | 1.00 | TOP1 (0.79) | TOP1ALDH1A1GLAMEN1KMT2A | |
| Gimatecan SCHEMBL130586 | 1.00 | TOP1 (0.79) | TOP1ALDH1A1GLAMEN1KMT2A | |
| Gimatecan SCHEMBL27721325 | 1.00 | TOP1 (0.79) | TOP1ALDH1A1GLAMEN1KMT2A | |
| Gimatecan SCHEMBL29358288 | 1.00 | TOP1 (0.79) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL3181051 | 0.93 | TOP1 (0.76) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL25932531 | 0.92 | TOP1 (0.68) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL22843988 | 0.92 | TOP1 (0.81) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL2028767 | 0.92 | TOP1 (0.81) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL2028388 | 0.92 | TOP1 (0.85) | TOP1ALDH1A1GLAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743122-A1 | THERAPEUTIC SEALANTS BASED UPON DRUG CONJUGATES | The Johns Hopkins University (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4588485-A1 | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND TOPOISOMERASE INHIBITOR AND USE THEREOF | Inxmed (Nanjing) Co., Ltd. (CN) | 2025-07-23 | — | — | EP | claimed |
| US-20250032627-A1 | THERAPEUTIC SEALANTS BASED UPON DRUG CONJUGATES | INTEGRA LIFESCIENCES CORPORATION | 2025-01-30 | — | — | US | claimed |
| WO-2025019210-A1 | THERAPEUTIC SEALANTS BASED UPON DRUG CONJUGATES | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-01-23 | — | — | WO | claimed |
| US-20240226308-A1 | DOSING REGIMENS OF PEPTIDE CONJUGATES OF TOPOISOMERASE I INHIBITORS | Cybrexa 2, Inc. | 2024-07-11 | — | — | US | claimed |
| WO-2024056074-A1 | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND TOPOISOMERASE INHIBITOR AND USE THEREOF | 应世生物科技(南京)有限公司 | 2024-03-21 | — | — | WO | claimed |
| EP-4329817-A1 | DOSING REGIMENS OF PEPTIDE CONJUGATES OF TOPOISOMERASE I INHIBITORS | Cybrexa 2, Inc. (US) | 2024-03-06 | — | — | EP | claimed |
| US-20230338363-A1 | COMBINATION CHEMO-IMMUNOTHERAPY FOR PANCREATIC CANCER USING THE IMMUNOGENIC EFFECTS OF AN IRINOTECAN SILICASOME NANOCARRIER PLUS ANTI-PD-1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | US | claimed |
| CN-115969970-A | Combination of an ABCG2 inhibitor and SACITUZUMAB GOVITECAN | 免疫医疗公司 | 2023-04-18 | — | — | CN | claimed |
| WO-2022262516-A1 | LINKER AND CONJUGATE THEREFOR | 北京海步医药科技有限公司 | 2022-12-22 | — | — | WO | claimed |
| WO-2022232808-A1 | DOSING REGIMENS OF PEPTIDE CONJUGATES OF TOPOISOMERASE I INHIBITORS | Cybrexa 2, Inc. (US) | 2022-11-03 | — | — | WO | claimed |
| US-20220249473-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-08-11 | — | — | US | claimed |
| EP-3997093-A1 | PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS | Cybrexa 2, Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| CN-114341162-A | Peptide conjugates of cytotoxins as therapeutic agents | 赛博克萨2公司 | 2022-04-12 | — | — | CN | claimed |
| EP-3972605-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | University of Pittsburgh - of the Commonwealth System of Higher Education (US) | 2022-03-30 | — | — | EP | claimed |
| CN-114096250-A | Novel therapy for erythropoietic protoporphyrinopathy (EPP) and X-linked protoporphyrinopathy (XLP) | 匹兹堡大学联邦高等教育系统 | 2022-02-25 | — | — | CN | claimed |
| EP-4743122-A1 | THERAPEUTIC SEALANTS BASED UPON DRUG CONJUGATES | The Johns Hopkins University (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-1859797-A1 | NOVEL CONCOMITANT USE OF SULFONAMIDE COMPOUND WITH ANTI-CANCER AGENT | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | disclosed |
| EP-1759699-A1 | LIPOSOME PREPARATION CONTAINING SLIGHTLY WATER-SOLUBLE CAMPTOTHECIN | TERUMO KABUSHIKI KAISHA (JP) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226308-A1 | DOSING REGIMENS OF PEPTIDE CONJUGATES OF TOPOISOMERASE I INHIBITORS | TOP1, TOP2A, TOP2B | TOP1 1/4885ALDH1A1 4598/4885GLA 2594/4885 |
| US-20220249473-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | XPA, TPX2, XPOT | TOP1 1624/4885ALDH1A1 1427/4885GLA 1448/4885 |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR3C1, NCOR1 | TOP1 696/4885ALDH1A1 2758/4885GLA 2265/4885 |
| US-20230338363-A1 | COMBINATION CHEMO-IMMUNOTHERAPY FOR PANCREATIC CANCER USING THE IMMUNOGENIC EFFECTS OF AN IRINOTECAN SILICASOME NANOCARRIER PLUS ANTI-PD-1 | SQSTM1, PDCD1, CD274 | TOP1 33/4885ALDH1A1 2695/4885GLA 2539/4885 |
| US-20250032627-A1 | THERAPEUTIC SEALANTS BASED UPON DRUG CONJUGATES | CD44, GRPR, EPCAM | TOP1 2636/4885ALDH1A1 1107/4885GLA 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.